RESUMEN
Objective:To explore the clinical efficacy of Gemcitabine in combination with radiotherapy for elderly patients with cervical cancer .Methods:From December 2016 to August 2018, 84 elderly patients with advanced cervical cancer receiving treatment in our hospital were enrolled.As a randomized controlled study, patients were divided into the radiotherapy-alone group and the combined therapy group.Patients in the combined therapy group was given radiotherapy and Gemcitabine.The short- and long-term efficacy, and the rate of adverse reactions were evaluated for the two groups.Results:Tumors in both groups were effectively controlled after treatment.The overall rate of effectiveness in the radiotherapy-alone group was significantly lower than that in the combined therapy group(67.6% vs.87.2%, χ2=4.756, P=0.029). The combined therapy group was associated with a significantly higher survival rate(89.4% vs.59.5%, χ2=10.204, P=0.001), a local recurrence-free rate(83.0% vs.54.1%, χ2=8.286, P=0.004), and a distant metastasis-free survival rate(83.0% vs.56.8%, χ2=6.975, P=0.008), compared with the radiotherapy-alone group.Additionally, the incidence of leukopenia was higher in the combined therapy group than in the radiotherapy-alone group(38.3% vs.13.5%, χ2=8.396, P=0.011). Conclusion:The combination of radiotherapy with Gemcitabine for the treatment of advanced cervical cancer in elderly patients can effectively enhance control on cancerous tissues, improve the long-term survival rate, and reduce the risk of local recurrence.